Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial

MLA

Ryujiro Suzuki, et al. “Phase I and Pharmacologic Study of Weekly Amrubicin in Patients with Refractory or Relapsed Lung Cancer: Central Japan Lung Study Group (CJLSG) 0601 Trial.” Cancer Chemotherapy and Pharmacology, vol. 69, no. 5, Sept. 2011. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a7d7d4f4f1a0bc0a806e13850de9e0fb&authtype=sso&custid=ns315887.

APA

Ryujiro Suzuki, Hideo Saka, Masahide Oki, Shigehisa Kajikawa, Chiyoe Kitagawa, & Kouki Mori. (2011). Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial. Cancer Chemotherapy and Pharmacology, 69(5).

Chicago

Ryujiro Suzuki, Hideo Saka, Masahide Oki, Shigehisa Kajikawa, Chiyoe Kitagawa, and Kouki Mori. 2011. “Phase I and Pharmacologic Study of Weekly Amrubicin in Patients with Refractory or Relapsed Lung Cancer: Central Japan Lung Study Group (CJLSG) 0601 Trial.” Cancer Chemotherapy and Pharmacology 69 (5). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a7d7d4f4f1a0bc0a806e13850de9e0fb&authtype=sso&custid=ns315887.